109 related articles for article (PubMed ID: 21269563)
21. [Application of SNP-arrays in hematological malignancies - review].
Yang F; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):496-9. PubMed ID: 19379597
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
[TBL] [Abstract][Full Text] [Related]
23. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of hematological malignancies and peripheral cytopenias.
Jha A
J Nepal Health Res Counc; 2013 Sep; 11(25):273-8. PubMed ID: 24908530
[TBL] [Abstract][Full Text] [Related]
25. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.
de Lange P; Segeren CM; Koper JW; Wiemer E; Sonneveld P; Brinkmann AO; White A; Brogan IJ; de Jong FH; Lamberts SW
Cancer Res; 2001 May; 61(10):3937-41. PubMed ID: 11358809
[TBL] [Abstract][Full Text] [Related]
26. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
Zhang SJ; Shi JY; Li JY
Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
[TBL] [Abstract][Full Text] [Related]
27. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
28. Patterns of hematological and non-hematological malignancies in bone marrow in a tertiary care hospital in Nepal--11 years study.
Ghartimagar D; Ghosh A; Narasimhan R; Talwar OP
Nepal Med Coll J; 2012 Sep; 14(3):187-92. PubMed ID: 24047012
[TBL] [Abstract][Full Text] [Related]
29. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies.
Moosavi SA; Sanchez J; Adeyinka A
Cancer Genet Cytogenet; 2009 Feb; 189(1):24-8. PubMed ID: 19167608
[TBL] [Abstract][Full Text] [Related]
30. Hematological malignancy associated with polymyositis and dermatomyositis.
Marie I; Guillevin L; Menard JF; Hatron PY; Cherin P; Amoura Z; Cacoub P; Bachelez H; Buzyn A; Le Roux G; Ziza JM; Brice P; Munck JN; Sarrot-Reynauld F; Piette JC; Larroche C
Autoimmun Rev; 2012 Jul; 11(9):615-20. PubMed ID: 22079677
[TBL] [Abstract][Full Text] [Related]
31. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.
Jacoby MA; Walter MJ
Expert Rev Mol Diagn; 2012 Apr; 12(3):253-64. PubMed ID: 22468816
[TBL] [Abstract][Full Text] [Related]
32. Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005).
Gluzman D; Imamura N; Sklyarenko L; Nadgornaya V; Zavelevich M; Machilo V
Exp Oncol; 2006 Mar; 28(1):60-3. PubMed ID: 16614710
[TBL] [Abstract][Full Text] [Related]
33. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals.
Kiss TL; Chang H; Daly A; Messner HA; Jamal N; Spaner D; Rubin S; Lipton JH
Bone Marrow Transplant; 2004 Apr; 33(8):855-8. PubMed ID: 14990983
[TBL] [Abstract][Full Text] [Related]
35. Jumping translocations in hematological malignancies: a cytogenetic study of five cases.
Manola KN; Georgakakos VN; Stavropoulou C; Spyridonidis A; Angelopoulou MK; Vlachadami I; Katsigiannis A; Roussou P; Pantelias GE; Sambani C
Cancer Genet Cytogenet; 2008 Dec; 187(2):85-94. PubMed ID: 19027489
[TBL] [Abstract][Full Text] [Related]
36. The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods.
Xu X; Johnson EB; Leverton L; Arthur A; Watson Q; Chang FL; Raca G; Laffin JJ
Cancer Genet; 2013; 206(9-10):317-26. PubMed ID: 24269304
[TBL] [Abstract][Full Text] [Related]
37. Leukemia and myelodysplastic syndrome in granulomatosis with polyangiitis: subtypes, clinical characteristics, and outcome.
Knight A; Hjorton K; Sundström C; Höglund M; Backlin C; Smedby KE; Askling J; Baecklund E
J Rheumatol; 2015 Apr; 42(4):690-4. PubMed ID: 25641890
[TBL] [Abstract][Full Text] [Related]
38. Copy number variations of Interleukin-12B and T-bet are associated with systemic lupus erythematosus.
Yu B; Shao Y; Yue X; Zhang J; Guan M; Wan J; Zhang W
Rheumatology (Oxford); 2011 Jul; 50(7):1201-5. PubMed ID: 21278068
[TBL] [Abstract][Full Text] [Related]
39. Copper levels in patients with hematological malignancies.
Kaiafa GD; Saouli Z; Diamantidis MD; Kontoninas Z; Voulgaridou V; Raptaki M; Arampatzi S; Chatzidimitriou M; Perifanis V
Eur J Intern Med; 2012 Dec; 23(8):738-41. PubMed ID: 22920946
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA.
Coccaro N; Anelli L; Zagaria A; Tarantini F; Cumbo C; Tota G; Minervini CF; Minervini A; Conserva MR; Redavid I; Parciante E; Macchia MG; Specchia G; Musto P; Albano F
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
